Citigroup Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to a hold rating in a research report released on Wednesday morning,Zacks.com reports.

REGN has been the subject of a number of other reports. Barclays cut their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Leerink Partners restated a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $26.59 on Wednesday, hitting $755.92. 394,565 shares of the company traded hands, compared to its average volume of 526,043. The business’s 50 day moving average price is $992.70 and its 200-day moving average price is $1,033.92. Regeneron Pharmaceuticals has a 52-week low of $753.69 and a 52-week high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $83.07 billion, a price-to-earnings ratio of 18.93, a P/E/G ratio of 3.04 and a beta of 0.15.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of REGN. Sachetta LLC lifted its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $26,000. Finally, Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.